The global mucinoses management market is expected to reach a valuation of USD 112.81 million in 2023 and is projected to exhibit a CAGR of 19.5% from 2023 to 2033, reaching USD 669.95 million.
The mucinoses management market is projected to expand as a result of numerous variables influencing the healthcare industry, such as greater government investment in studies and development, along with substantial changes implemented into the system to allow numerous medical professionals to focus not solely on providing adequate quantity is handled, but also on ensuring the level of service is not undermined by medical providers. In 2017, the EU's government spending on healthcare was documented at USD 1,221 million, accounting for approximately 7.1% of GDP.
An increase in the volume of studies and development associated with topical corticosteroids by market participants is anticipated to aid in expanding topical corticosteroids by market participants is anticipated to aid in the expansion of the topical corticosteroids (steroids) segment over the projected timeframe, contributing to the industry's development. For instance, in April 2022, the global pharmaceutical company Eli Lilly and Company declared that Lebrikizumab, an IL-13 inhibitor, drastically enhanced treatment response when merged with topical corticosteroids (TCS) in individuals with mild-to-severe atopic dermatitis (AD) in the 3rd pivotal Phase 3 trial (ADhere). Moreover, the growing cases of skin-related illnesses, such as skin irritation, dermatitis, itchiness, eczema, and psoriasis, have contributed to the growth of the corticosteroid injections segment, which will push market growth even further.
SHJCM (self-healing juvenile cutaneous mucinosis) is a rare condition with fewer than 20 reported incidents globally. Based on the rarediseaseday.org February 2022 update, approximately 300 million individuals around the world live with rare diseases, which is an incredibly large number. As a result, the requirement for efficient and sophisticated treatment methods for rare conditions is predicted to rise. due to the substantial liability and heightened awareness about such diseases, which is anticipated to drive growth in the researched market during the forecast period.
The increased incidences of head and neck cancer will be a prime motivator factor for the expansion of the North American drastic oral mucositis market over the coming years. The major players in the United States are concentrating on raising funds to augment studies and development for treating chronic oral mucositis in cancer sufferers caused by radiation therapy and chemotherapy. Thus, owing to this factor North America is expected to witness market growth. The expansion of Asia Pacific can be credited to government schemes to assist orphan illness patients. For instance, the Indian government oriented federal and state governments in July 2022 to make sure that the implementation of healthcare programs evolved to treat patients experiencing orphan diseases. As a result, this aspect will have an impact on the Asia Pacific mucinoses management market over the upcoming decades.
In the midst of global challenges, market participants have begun to seek safe investments by concentrating on emerging technology and product releases. As the US government stands focused on quality by stimulating demand for Medicaid and Medicare, federal subsidies to medical equipment, pharmaceutical, and biotech companies will profit market participants in both short and long-term goals. In 2021, the United States spent USD 12,318 per individual on health coverage, the most of any OECD country, preceded by Germany at USD 7,383. The federal government's approach to healthcare systems will allow market makers to increase their earnings while minimizing the threat posed by inflation, resulting in market growth.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 112.81 Million |
| Anticipated Forecast Value (2033) | USD 669.95 Million |
| Projected Growth Rate (2023 to 2033) | 19.5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The coronavirus (COVID-19) pandemic and shutdown in different parts of the world have had an economic effect on corporations of all sizes. The COVID-19 pandemic has had a substantial effect on the private medical industry. Furthermore, the coronavirus pandemic has had an adverse effect on the development, manufacturing, and delivery of pharmaceutical drugs, along with the expansion of many oral mucositis medication firms around the world. From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 18%.
However, now, that the industries are getting back to their normal functioning, the global demand for mucinoses management market is projected to increase at a CAGR of 19.5% during the forecast period between 2023 and 2033, reaching a total of USD 669.95 Million in 2033, according to a report from Future Market Insights (FMI).
A Rich Investment Landscape Facilitated by the Presence of Key Market Players driving Growth
The key participants are concentrating on investment initiatives in order to enhance studies and innovations for the treatment of serious oral mucositis in cancer survivors prompted by radiation and chemotherapy. Galera Therapeutics, Inc., for instance, revealed in September 2018 that it had assured USD 150 million in a combined, received Series C financing and royalty purchase agreement.
Clarus directed the funding, which was co-led by Adage Capital Management, HBM Healthcare Investments, Nan Fung Life Sciences, RA Capital, Rock Springs Capital, and Tekla Capital Management LLC. Correlation Ventures, Galera Angels, New Enterprise Associates, Novartis Venture Fund, Novo Ventures, and Sofinnova Ventures were among the bondholders who took part.
Multiple and Innovative Expansion Strategies drive Market Growth
A comprehensive strategy based on breakthrough initiatives for the development of novel SMA medicines to address unmet medical needs in rare disease therapeutics is predicted to propel industry growth.
In June 2021, for instance, the European expert group on orphan drug incentives released a package of policy initiatives to address unmet healthcare needs in rare conditions. This proposed policy involves a modification of the EMA's pharma strategy and orphan drug laws in order to encourage Capital investments in orphan drugs. As a result, this factor is expected to fuel market growth.
Principal Consultant
High Costs may hinder Market Growth
The high additional cost related to severe mucositis in cancer patients is one of the main factors impeding overall growth. Based on a 2019 study published by Oxford University Press, patients receiving chemotherapy and radiation therapy for the diagnosis of head and neck cancers must incur an additional expense for the treatment of side effects such as serious mucositis.
As per the same source, patients must pay an additional USD 5,000-30,000 for the treatment of mucositis resulting from radiation therapy, while patients must pay an extra USD 3,700 per loop for oral mucositis caused by chemotherapeutics in the United States.
Increased Prevalence of Cancer to drive the adoption of Mucinoses Management
The increased incidence of head and neck cancer area major driver of the North American mucositis management market in the coming years. Based on the American Society of Clinical Oncology's (ASCO) 2021 survey, roughly 4% of people in the United States had head and neck cancer, with an estimated 66,630 people (48,740 men and 17,890 women) developing the disease.
The region's increasing geriatric population (aged 65 and up) is also a significant contributor to the industry's growth. According to Statista's most recent report, from 2011 to 2021, 17.04 percent of the people in the United States wereover the age of 65. The severe oral mucositis market in the United States wasexpected to be worth USD 79 million in 2021.
The Asia Pacific mucositis management market is anticipated to expand due to the various opportunities provided by the region's governments' soaring healthcare spending. For example, as per World Bank data, existing health expenditure per capita in Japan increased from USD2,754.38 in 2006 to USD 4,360.47 in 2019. Healthcarespending as a percentage of national GDP obtained 10.74% in 2019, up from 7.69% in 2006.
Furthermore, Asia Pacific is predicted to be the fastest-growing region in the treatment of rare diseases. The region's expansion can be credited to government schemes to assist orphan disorder patients. For instance, the Indian government directed the federal and state governments in July 2022 to make sure that the implementation of healthcare programs wasestablished to treat patients experiencing orphan diseases. This assessment allows companies to provide high-quality orphan drugs to the administration while also total revenues. As a result, this aspect will contribute to industry growth.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Eczema and Atopic DermatitispropelTopical Corticosteroids Segment Growth
Over the forthcoming years, the growing number of studies and developments associated withtopical corticosteroids by market participants is anticipated to aid in the expansion of the topical corticosteroids (steroids) industry. Eczema and atopic dermatitis are predicted to drive thetopical corticosteroids segment's growth in themarket.
Key players in the Mucinoses Management market are Gsk plc, Almirall, S.A, Merck & Co., Inc, Bausch Health, Sandoz International GmbH, Pfizer Inc, AstraZeneca, Sanofi, Alencure Biotech, Divine Laboratories. Some of the latest developments by key manufacturers are below
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 112.81 Million |
| Market Value in 2033 | USD 669.95 Million |
| Growth Rate | CAGR of 19.5% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Drug Class, Route of Administration, Distribution Channel, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East & Africa |
| Key Countries Profiled | United States, Canada, Brazil, Mexico, Mexico, Germany, United Kingdom, France, Spain, Italy, Indonesia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | GSK Plc.; Almirall, S.A; Merck & Co., Inc.; Bausch Health; Sandoz International GmbH; Pfizer Inc.; AstraZeneca; Sanofi; Alencure Biotech; Divine Laboratories |
| Customization | Available Upon Request |
The market is valued to hit USD 669.95 million by 2033.
The market is forecast to register a CAGR of 19.5% through 2033.
The market is estimated to secure a valuation of USD 112.81 million in 2023.
During 2018 to 2022, the market evolved at a CAGR of 18%.
A thriving investment environment made possible by the presence of significant market players fostering growth.
Considerable additional expense associated with severe mucositis in cancer patients.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Topical Corticosteroids 5.2. Corticosteroid Injections 5.3. Oral Antibiotics 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 6.1. Oral 6.2. Intralesional 6.3. Topical 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Hospital Pharmacies 7.2. Retail Pharmacies 7.3. Others 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. Asia Pacific 8.5. Middle East & Africa 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Key Countries Market Analysis 15. Market Structure Analysis 16. Competition Analysis 16.1. GSK Plc. 16.2. Almirall, S.A. 16.3. Merck & Co., Inc. 16.4. Bausch Health 16.5. Sandoz International GmbH 16.6. Pfizer Inc. 16.7. AstraZeneca 16.8. Sanofi 16.9. Alencure Biotech 16.10. Divine Laboratories 17. Assumptions & Acronyms Used 18. Research Methodology
Explore Healthcare Insights
View Reports
Mucinoses Management Market
